Matrix metalloproteinase-2 (MMP-2) is known to degrade type IV collagen, which is a major component of the cellular basement membrane, and to be involved in the invasion and metastasis of cancer cells. On the other hand, C-reactive protein (CRP) and serum amyloid A (SAA) are acute inflammatory biomarkers that increase in various conditions including infection, inflammation, malignancy and tissue disturbance. In the present study, we examined the serum levels of MMP-2, CRP and SAA in patients with localized and metastatic non-small cell lung cancer (NSCLC) to establish the clinical significance and changes in these biomarkers during NSCLC progression. In this study, 24 NSCLC patients were diagnosed at the Kitasato University Hospital and compared with 13 healthy controls. Measurement of MMP-2 levels in serum was determined by measuring pro-MMP-2 using a one-step sandwich enzyme immunoassay. CRP and SAA levels in the serum were measured by latex nephelometry. The serum levels of MMP-2, CRP and SAA in metastatic NSCLC patients were significantly higher than in localized NSCLC patients (p<0.01). There was a significant positive correlation between serum MMP-2 and CRP levels as well as SAA levels in metastatic NSCLC patients (p<0.01). Therefore, quantitation of MMP-2, CRP and SAA in NSCLC patients may be an auxiliary indicator to monitor tumor progression and poor prognosis of NSCLC disease.
Matrix metalloproteinases (MMPs) are a group of zinc-dependent endopeptidases that are known to degrade extracellular matrix (ECM). MMPs are secreted as inactive zymogens from cancer cells or macrophages and activated by proteases such as plasmin or trypsin (1,2). Biological activities of MMPs are downregulated by α2-macroglobulin (α2M) or tissue inhibitors of metalloproteinases (TIMPs) produced by macrophages, fibroblasts or other types of cells (3–5). Therefore, a quantitative imbalance between MMPs and their inhibitors such as α2M and TIMPs is thought to be a causative factor in invasion and metastasis. It has also been shown that MMP-2 degrades the ECM of atherosclerotic plaques and has an important role in plaque vulnerability at atherosclerotic regions (6,7). We previously reported that the quantitative imbalance between proteases, such as prostate-specific antigen (PSA) and MMP-2, and their inhibitors, including α2M and α2-plasmin inhibitor, is a causative factor in invasion and metastasis of prostate cancer (PCa) (8,9).
C-reactive protein (CRP) and serum amyloid A (SAA) are widely used as acute inflammatory biomarkers in various conditions such as infection, inflammation, malignancy and tissue disturbance (10–12). CRP is most widely used as a sensitive inflammatory biomarker in routine clinical examination. In recent years, the determination of high sensitivity CRP (hs-CRP) has been possible due to the wide use of low concentration range measurements in routine clinical examination. It has been demonstrated that hs-CRP reflects the degree of localized vascular inflammation and is a useful prognostic marker of cardiovascular events (13,14). On the other hand, serum SAA level is generally increased in patients with viral infection or in corticosteroid-treated patients in contrast to CRP (15,16). The production of CRP and SAA in liver cells is regulated by interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) secreted from macrophages in various conditions (17,18). α2M is the most abundant proteinase inhibitor in the blood, and it is also involved in the inflammatory reaction through its function as a carrier protein of IL-6 (19). We previously demonstrated that the serum levels of IL-6, CRP and SAA were affected by serum α2M concentration in PCa patients with or without α2M deficiency, and these markers are considered α2M-dependent acute inflammatory biomarkers (20,21).
However, the relationship between the serum levels of MMP-2 and acute inflammatory biomarkers in patients with NSCLC progression has yet to be demonstrated. Therefore, we quantified serum levels of MMP-2, CRP and SAA in localized and metastatic NSCLC patients to establish the clinical significance and changes of these biomarkers during NSCLC disease progression. Although this study includes only a limited number of NSCLC patients, it is the first report to investigate the clinical significance and changes of MMP-2, CRP and SAA in patients with NSCLC in relation to disease progression.
Materials and methodsPatients
Thirty-seven untreated adult men participated in this study, of whom 13 were healthy controls (mean age 62.6 years, range 53–72) and 24 were diagnosed with non-small cell lung cancer (NSCLC) at the Kitasato University Hospital. The 24 cases included 12 localized NSCLC (6 adenocarcinomas and 6 squamous cell carcinomas) (mean age 64.8 years, range 52–78) and 12 metastatic NSCLC (6 adenocarcinomas and 6 squamous cell carcinomas) (mean age 67.6 years, range 54–79). NSCLC was clinically staged according to the TNM classification (22). Serum α2M levels in the 24 NSCLC patients and the 13 healthy controls were within reference range. Serum samples were obtained from these patients and stored at −80°C until use. Informed consent was obtained from all subjects in this study.
Acute inflammatory biomarkers
The measurement of MMP-2 levels in serum was determined by measuring pro-MMP-2 using a one-step sandwich enzyme immunoassay (Fuji Chemical Industries, Toyama, Japan) (23). CRP and SAA levels in serum were measured by latex nephelometry using the LX-M (Eiken Chemical Co., Tokyo, Japan).
Statistical analysis
The Wilcoxon signed-rank test and the Mann-Whitney U test were used for statistical analyses, and p<0.05 was considered to indicate statistically significant differences.
Ethics approval
This study was conducted in accordance with the Declaration of Helsinki. This study had no impact on the management of patients, and informed consent was obtained from all subjects.
ResultsConcentrations of MMP-2, CRP and SAA in serum
Table I shows the concentrations (median value, range) of MMP-2, CRP and SAA in the sera of healthy controls and NSCLC patients. The serum levels of MMP-2 (Fig. 1), CRP (Fig. 2) and SAA (Fig. 3) in metastatic NSCLC patients were significantly higher than in healthy controls (p<0.01 for all three markers) and localized NSCLC patients (p<0.01 for all three markers).
Correlation between serum MMP-2 and CRP levels
There was a weak, but significant negative correlation between serum MMP-2 and CRP levels in localized NSCLC patients (r2=0.042) (p<0.05) (Fig. 4). On the other hand, there was a weakly significant positive correlation between serum MMP-2 and CRP levels in metastatic NSCLC patients (r2=0.051) (p<0.01) (Fig. 5).
Correlation between serum MMP-2 and SAA levels
There was a significant positive correlation between serum MMP-2 and SAA levels in localized (r2=0.312) (p<0.01) (Fig. 6) and metastatic (r2=0.231) (p<0.01) (Fig. 7) NSCLC patients.
Discussion
MMPs are endopeptidases which degrade the ECM of the cellular basement membrane. Among members of the MMP family, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) have been shown to degrade type IV collagen which is a major component of the cellular basement membrane. Therefore, it is thought that MMP-2 and MMP-9 are associated with invasion and metastasis of cancer cells. Noh et al showed that MMP-2 concentration in ascites might be a prognostic marker in advanced gastric cancer patients with disseminated metastasis (24). It has also been reported that the expression of MMP-2 in body fluid can be used as an additive diagnostic marker for metastatic breast cancer patients (25). Safranek et al demonstrated that mRNA expression of MMP-7 and MMP-9 in lung tissue of patients with NSCLC is higher than in the surrounding tissue and in benign lung disease tissue, and these findings support the important roles of these MMPs in the growth of lung cancer (26). Furthermore, it has also been shown that high expression of MMP-9 is associated with poor prognosis in patients with NSCLC (27). In the present study, we demonstrated that serum MMP-2 levels were markedly increased in metastatic NSCLC patients as compared to localized NSCLC. Therefore, it is hypothesized that MMP-2 is involved in the invasion and metastasis of NSCLC, as is the case with other types of cancer, and high serum MMP-2 levels in NSCLC patients can predict tumor progression.
CRP is a plasma protein produced by liver cells following cytokine stimulation, mainly IL-6, but also IL-1β and TNF-α (17,18). Serum CRP levels are increased in various conditions including infection, inflammation and tissue disturbance such as malignancy or myocardial infarction, but serum CRP levels are rarely increased in viral infection, multiple myeloma and non-active systemic lupus erythematosus (15,28,29). It has been shown that elevated serum CRP levels are associated with tumor progression and poor prognosis of esophageal cancer (12). Chua et al demonstrated that inflammatory and tumor markers in serum predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cyto-reduction and intra-peritoneal chemotherapy (30). It has also been reported that elevated preoperative serum CRP levels predict poor survival in patients undergoing resection for NSCLC (31).
SAA is a plasma protein produced by liver cells following cytokine stimulation, mainly IL-1β, but also IL-6 and TNF-α, and is generally increased in patients with viral infection and corticosteroid treatment, a characteristic that differs from CRP (17,18). The degree of change in serum SAA levels is believed to be larger compared to CRP in various conditions, and IL1-β stimulation of SAA production is hard to suppress by corticosteroid treatment (16). It has been reported that serum SAA levels are useful in predicting survival of patients with gastric cancer (32). Cocco et al demonstrated that SAA may be a novel biomarker to monitor disease recurrence and response to therapy in patients with uterine serous papillary cancer (33). It has also been shown that elevated serum SAA levels may be used as a potential biomarker for gastric cancer (34). In this study, serum CRP and SAA levels in metastatic NSCLC patients were significantly higher than in healthy controls and localized NSCLC patients, and there was a significant positive correlation between serum MMP-2 and CRP levels as well as SAA levels in metastatic NSCLC patients. Elevated serum levels of CRP and SAA in metastatic NSCLC patients are considered to reflect the tissue disturbance and inflammation that are associated with invasion and metastasis of NSCLC, and high serum CRP and SAA levels can predict tumor progression and poor prognosis of NSCLC.
In conclusion, the present study demonstrated that serum MMP-2 levels were notably increased in metastatic NSCLC patients. Furthermore, serum levels of CRP and SAA were also markedly increased with NSCLC disease progression, and there was a significant positive correlation between serum MMP-2 and these acute inflammatory biomarkers in metastatic NSCLC patients. Therefore, the measurement of MMP-2, CRP and SAA in NSCLC patients may be an auxiliary indicator to monitor tumor progression and poor prognosis of NSCLC.
Acknowledgements
This study was supported by grants from the Ministry of Education, Culture, Sports and Technology (A11771512) and the Parents’ Association Grant of Kitasato University, School of Medicine.
ReferencesBaramovaENBajouKRemacieAL’HoirCKrellHWWeidleUHFoidartJMInvolvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activationFEBS Lett4051571621997MoneaSLehitKKeski-OjaMignatiiPPlasmin activates pro-matrix metalloproteinases-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanismJ Cell Physiol1921601702002ArbeláezLFBergmannUTuuttilaAShanbhagVPStigbrandTInteraction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and α2-macroglobulinArch Biochem Biophys34762681997BeekmanBDrijfhoutJWRondayHKTekoppeleJMFluorogenic MMP activity assay for plasma including MMPs complexed to α2-macroglobulinAnn NY Acad Sci8781501561999ChenWTWangJYSpecialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2 and TIMP-2 localizationAnn NY Acad Sci8783613701999DingSZhangMZhaoYChenWYaoGZhangCZhangPZhangYThe role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic strokeAm J Med Sci33627312008AlvarezBRuizCChaconPAlvarez-SabinJMatasMSerum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosisJ Vasc Surg404694752004KanohYAkahoshiTOharaTOhtaniNMashikoTOhtaniSEgawaSBabaSExpression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancerAnticancer Res22181318182002KanohYOhtaniHEgawaSBabaSAkahoshiTChanges of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiencyClin Lab582172252012KanohYOhtaniHLevels of interleukin-6, CRP and α2-macrogloburin in cerebrospinal fluid (CSF) and serum as indicator of blood-CSF barrier damageBiochem Mol Biol Int432692781997dos AnjosBLGrottoHZEvaluation of C-reactive protein and serum amyloid A in the detection of inflammatory and infectious disease in childrenClin Chem Lab Med484934992010FujiwaraHSuchiKOkamuraHUmeharaSTodaMShiozakiAKubotaTIchikawaDOkamotoKOchiaiTKokubaYSonoyamaTOtsujiEElevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancerJ Surg Oncol10362682011ImazioMBrucatoAMaestroniSCumettiDDominelliANataleGTrincheroRPrevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implication for the diagnosis, therapy, and prognosis of pericarditisCirculation213109210972011Kablak-ZiembickaAPrzewlockiTSokolowskiATraczWPodolecPCarotid intima-media thickness, hs-CRP and TNF-α are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive diseaseAtherosclerosis2141851902011KanohYOharaTAkahoshiTAcute inflammatory biomarkers in cerebrospinal fluid as indicators of blood cerebrospinal fluid barrier damage in Japanese subjects with infectious meningitisClin Lab5737462011SmithJWColomboJLMcDonaldTLComparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid cystic fibrosis patientsJ Clin Lab Anal62192241992YapSHMoshageHJHazenbergBPRoelofsMHBijizetJLimburgPCAardenLAvan RijiswijkMHTumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytesBiochim Biophys Acta10914054081991SmithJWMcDonaldTLProduction of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisoloneClin Exp Immunol902932991992MatsudaTHiranoTNagasawaSKishimotoTIdentification of α2 macroglobulin as a carrier protein for IL-6J Immunol1421481521989KanohYOhtaniHEgawaSBabaSAkahoshiTLevels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiencyInt J Oncol39155315582011KanohYOhtaniHEgawaSBabaSAkahoshiTClinicopathological characteristic of androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiencyInt J Oncol4139452012MountainCA new international staging system for lung cancerChest89S225S2331986FujimotoNMouriNIwataKOhuchiEOkadaYHayakawaTA one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodiesClin Chim Acta221911031993NohSJungJJJungMKimTSParkCHLimSJJeungHCCheolHChungHCRhaSYMMP-2 as a putative biomarker for carcinomatosis in gastric cancerHepatogastroenterology58201520192011NohSJungJJJungMKimTSParkCHLimSJJeungHCCheolHChungHCRhaSYBody fluid MMP-2 as a putative biomarker in metastatic breast cancerOncol Lett36997032012SafranekJPestaMHolubecLKuldaVDreslerovaJVrzalovaJTopolcanOPesekMFinekJTreskaVExpression of MMP-7, MMP-9 TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary diseaseAnticancer Res29251325172009PengWJZhangJQWangBXPanHELuMMWangJPrognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancerClin Chim Acta413112111262012BatailleRBoccadoroMKleinBDuriePileriAC-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging systemBlood807337371992FiroozNAlbertDWallaceDIshimoriMBerelDWeismanMHigh-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosusLupus205885972011ChuaTCChongCHLiauwWZhaoJMorrisDLInflammation markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapyAnn Surg2563423492012O’DowdCMcRaeLAMcMillianDCKirkAMilroyRElevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancerJ Thorac Oncol59889922010ChanDCChenCJChuHCChangWKYuJCChenYJWenLLHuangSCKuCHLiuYCChenJHEvaluation of serum amyloid A as a biomarker for gastric cancerAnn Surg Oncol1484932007CoccoEBelloneSEl-SahwiKCargneluttiMCasagrandeFBuzaNTavassoliFASiegelERVisintinIRatanrESilasiDAAzodiMSchwartzPERutherfordTJPecorelliSSantinADSerum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerBr J Cancer1013353412009LiuCPanCShenJWangHYongLIdentification of serum amyloid A in the serum of gastric cancer patients by protein expression profilingOncol Lett3125912622012
Serum MMP-2 levels in healthy controls, and localized and metastatic NSCLC patients. Serum MMP-2 levels were significantly increased in metastatic NSCLC patients as compared to healthy controls and localized NSCLC patients. NSCLC, non-small cell lung cancer; *p<0.01.
Serum CRP levels in healthy controls, and localized and metastatic NSCLC patients. Serum CRP levels were markedly increased in metastatic NSCLC patients as compared to healthy controls and localized NSCLC patients. NSCLC, non-small cell lung cancer; *p<0.01.
Serum SAA levels in healthy controls, and localized and metastatic NSCLC patients. Serum SAA levels were markedly increased in metastatic NSCLC patients as compared to healthy controls and localized NSCLC patients. NSCLC, non-small cell lung cancer; *p<0.01.
Correlation between serum MMP-2 and CRP levels in localized NSCLC patients. There was a weak but significant negative correlation between serum MMP-2 and CRP levels in localized NSCLC patients. NSCLC, non-small cell lung cancer.
Correlation between serum MMP-2 and CRP levels in metastatic NSCLC patients. There was a weakly significant positive correlation between serum MMP-2 and CRP levels in metastatic NSCLC patients. NSCLC, non-small cell lung cancer.
Correlation between serum MMP-2 and SAA levels in localized NSCLC patients. There was a significant positive correlation between serum MMP-2 and SAA levels in localized NSCLC patients. NSCLC, non-small cell lung cancer.
Correlation between serum MMP-2 and SAA levels in metastatic NSCLC patients. There was a significant positive correlation between serum MMP-2 and SAA levels in metastatic NSCLC patients. NSCLC, non-small cell lung cancer.
Concentration (median value, range) of MMP-2, CRP and SAA in healthy controls and NSCLC patients.